Yabao Pharmaceutical Group Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Ren Wei

Chief Executive Officer (CEO)

CN¥1.6m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	0.1%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Yabao Pharmaceutical Group's (SHSE:600351) Strong Earnings Are Of Good Quality

May 02

CEO

Ren Wei (37 yo)

no data

Permanencia

CN¥1,573,800

Compensación

Mr. Ren Wei serves as General Manager and Vice Chairman at Yabao Pharmaceutical Group Co., Ltd and served as its Deputy General Manager. Mr. Wei served as General manager in Beijing Yabao Investment Manage...

Yabao Pharmaceutical Group Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Yabao Pharmaceutical Group Co., Ltd, Annual General Meeting, May 16, 2024

Insufficient new directors

Insufficient new directors

Recent updates

Yabao Pharmaceutical Group's (SHSE:600351) Strong Earnings Are Of Good Quality

First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 1Q 2023)

Yabao Pharmaceutical Group Co., Ltd, Annual General Meeting, May 16, 2024

Yabao Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 18%

Yabao Pharmaceutical Group Co., Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Third quarter 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.008 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.079 (vs CN¥0.038 in 2Q 2022)

Yabao Pharmaceutical Group Co., Ltd (SHSE:600351) commences an Equity Buyback Plan for CNY 300 million worth of its shares, under the authorization approved on April 24, 2023.

First quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.093 in 1Q 2022)

Investor sentiment deteriorated over the past week

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.008 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.038 (vs CN¥0.045 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.045 (vs CN¥0.027 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.084 (vs CN¥0.052 in 1Q 2020)

New 90-day low: CN¥4.58

New 90-day low: CN¥4.60

New 90-day low: CN¥4.99

New 90-day low: CN¥5.09

New 90-day low: CN¥5.25

Third quarter earnings released

Yabao Pharmaceutical Group Co., Ltd to Report Q3, 2020 Results on Oct 24, 2020

Earnings released

New 90-day high - CN¥5.73

Yabao Pharmaceutical Group Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

CEO

Permanencia

Compensación